Overview
- Third-quarter net revenue rose 9.1% to $15.78 billion, exceeding consensus estimates.
- Adjusted EPS came in at $1.86, down 38% year over year yet above the $1.79 estimate; GAAP diluted EPS was reported at $0.10.
- Full-year adjusted EPS guidance increased to $10.61–$10.65 per share, which incorporates a $2.05 per-share unfavorable impact from acquired IPR&D and milestone expenses year-to-date.
- The quarterly dividend was raised to $1.73 per share as leadership pointed to business momentum and pipeline progress.
- Immunology revenue reached $7.89 billion with Skyrizi at $4.71 billion (+46.8%) and Rinvoq at $2.18 billion (+35.3%) offsetting Humira’s decline to $993 million, while neuroscience rose to $2.84 billion with gains from Vraylar and Botox Therapeutics.